Investment is expected to bring approximately 1,000 new jobs at Novartis and 4,000 additional roles across the United States.

Full approval of Vitrakvi was based on results from three clinical trials in patients with unresectable or metastatic NTRK ...

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra ...

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses Juvena’s "pipeline in a product" JUV-161 and plans to broaden into other disease indications.

Financing of Merida Biosciences was backed by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, with ...

As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not ...

PharmaLogic states that the acquisition of Agilera Pharma AS will place the company in a unique global role in ...

Davidi Vortman, CEO, UltraSight, discusses how AI-powered heart scan technology can help high-risk cardiovascular disease ...

The survey also suggests that Medicaid is broadly popular amongst all Americans, regardless of political affiliation.

Brimochol PF, a combination of brimonidine and carbachol, was found to enhance depth of focus and visual acuity in clinical ...

Hyfe’s CEO Tamsin Chislett spoke with Pharmaceutical Executive about this new technology, along with how digital therapeutics ...

Approval of the Opdivo plus Yervoy combination regimen was based on results from the Phase III CheckMate-8HW trial, which was ...